These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 6791202

  • 21. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB, Weinstock M.
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [Abstract] [Full Text] [Related]

  • 22. The inhibition of tyramine oxidation and the tyramine hypertensive response ("cheese effect") may be independent phenomena.
    Sandler M, Glover V, Ashford A, Esmail A.
    J Neural Transm; 1980 Jan; 48(4):241-7. PubMed ID: 6775051
    [Abstract] [Full Text] [Related]

  • 23. Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens.
    Finberg JP, Tenne M.
    Br J Pharmacol; 1982 Sep; 77(1):13-21. PubMed ID: 6127132
    [Abstract] [Full Text] [Related]

  • 24. Monoamine oxidase B inhibition and the "cheese effect".
    Youdim MB, Finberg JP.
    J Neural Transm Suppl; 1987 Sep; 25():27-33. PubMed ID: 3480939
    [Abstract] [Full Text] [Related]

  • 25. limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30.
    Gal S, Abassi ZA, Youdim MB.
    Neurotox Res; 2010 Aug; 18(2):143-50. PubMed ID: 19894083
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Absence of "cheese effect" during deprenyl therapy: some recent studies.
    Sandler M, Glover V, Ashford A, Stern GM.
    J Neural Transm; 1978 Aug; 43(3-4):209-15. PubMed ID: 745013
    [Abstract] [Full Text] [Related]

  • 30. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain.
    Olmos G, Gabilondo AM, Miralles A, Escriba PV, García-Sevilla JA.
    Br J Pharmacol; 1993 Mar; 108(3):597-603. PubMed ID: 8385528
    [Abstract] [Full Text] [Related]

  • 31. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I, Youdim MB, Finberg JP.
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [Abstract] [Full Text] [Related]

  • 32. Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect?
    Mendis N, Pare CM, Sandler M, Glover V, Stern GM.
    Psychopharmacology (Berl); 1981 Oct; 73(1):87-90. PubMed ID: 6785797
    [Abstract] [Full Text] [Related]

  • 33. Thyroid iodide transport is reduced by administration of monoamine oxidase A inhibitors to rats.
    Cabanillas AM, Masini-Repiso AM, Costamagna ME, Pellizas C, Coleoni AH.
    J Endocrinol; 1994 Nov; 143(2):303-8. PubMed ID: 7829993
    [Abstract] [Full Text] [Related]

  • 34. The effect of various MAO-B inhibitors on rabbit arterial strip response to tyramine.
    Abdorubo A, Knoll J.
    Pol J Pharmacol Pharm; 1988 Nov; 40(6):673-83. PubMed ID: 3269534
    [Abstract] [Full Text] [Related]

  • 35. Effects of caroxazone, a reversible monoamine oxidase inhibitor, on the pressor response to intravenous tyramine in man.
    Martini A, Bonollo L, Nicolis FB, Sega R, Palermo A, Braibanti E.
    Br J Clin Pharmacol; 1981 Jun; 11(6):605-10. PubMed ID: 7272177
    [Abstract] [Full Text] [Related]

  • 36. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers.
    Bieck PR, Firkusny L, Schick C, Antonin KH, Nilsson E, Schulz R, Schwenk M, Wollmann H.
    Clin Pharmacol Ther; 1989 Mar; 45(3):260-9. PubMed ID: 2920501
    [Abstract] [Full Text] [Related]

  • 37. Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.
    Schulz R, Antonin KH, Hoffmann E, Jedrychowski M, Nilsson E, Schick C, Bieck PR.
    Clin Pharmacol Ther; 1989 Nov; 46(5):528-36. PubMed ID: 2510962
    [Abstract] [Full Text] [Related]

  • 38. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition.
    Cattaneo C, Caccia C, Marzo A, Maj R, Fariello RG.
    Clin Neuropharmacol; 2003 Nov; 26(4):213-7. PubMed ID: 12897643
    [Abstract] [Full Text] [Related]

  • 39. [An increase in the radioprotective effect of O-methyltyramine and mezaton by monoamine oxidase inhibitors].
    Kulinskiĭ VI, Gorkin VZ, Klimova AD, Rumiantseva NP.
    Radiobiologiia; 1993 Nov; 33(1):137-40. PubMed ID: 8469735
    [Abstract] [Full Text] [Related]

  • 40. [Mechanism of inhibition by chlorgyline and deprenyl of tyramine deamination by mitochondrial monoamine oxidase of rat liver].
    Deverina IS.
    Biokhimiia; 1980 Oct; 45(10):1897-908. PubMed ID: 6786369
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.